Compare WKEY & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | SERA |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | Switzerland | United States |
| Employees | 102 | N/A |
| Industry | EDP Services | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 77.2M |
| IPO Year | N/A | 2021 |
| Metric | WKEY | SERA |
|---|---|---|
| Price | $7.26 | $2.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | 64.8K | ★ 69.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,000.00 |
| Revenue This Year | $31.22 | $25.84 |
| Revenue Next Year | $91.39 | $715.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.50 | $1.37 |
| 52 Week High | $19.80 | $4.20 |
| Indicator | WKEY | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 39.22 |
| Support Level | $6.24 | $1.37 |
| Resistance Level | $7.52 | $3.45 |
| Average True Range (ATR) | 0.43 | 0.20 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 37.43 | 39.65 |
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.